During the period, the European business reported maximum growth of 20 per cent to ₹733 crore, while India sales rose marginally by 0.4 per cent, held back by weak growth in the acute respiratory segment and a 10 per cent decline in diabetes market value due to new generic launches. Read more: https://pharma.economictimes.indiatimes.com/news/financial-performance/glenmark-pharmaceuticals-achieves-63-revenue-growth-in-q4-driven-by-strong-european-performance/121381939